These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30821928)

  • 1. Systematic Review of Recommendations on the Use of Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Cancer.
    Lopez-Olivo MA; Colmegna I; Karpes Matusevich AR; Qi SR; Zamora NV; Sharma R; Pratt G; Suarez-Almazor ME
    Arthritis Care Res (Hoboken); 2020 Mar; 72(3):309-318. PubMed ID: 30821928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: a systematic review.
    Lopez-Olivo MA; Kallen MA; Ortiz Z; Skidmore B; Suarez-Almazor ME
    Arthritis Rheum; 2008 Nov; 59(11):1625-38. PubMed ID: 18975351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
    Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
    Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety.
    Bombardier C; Hazlewood GS; Akhavan P; Schieir O; Dooley A; Haraoui B; Khraishi M; Leclercq SA; Légaré J; Mosher DP; Pencharz J; Pope JE; Thomson J; Thorne C; Zummer M; Gardam MA; Askling J; Bykerk V;
    J Rheumatol; 2012 Aug; 39(8):1583-602. PubMed ID: 22707613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review of recommendations on the use of methotrexate in rheumatoid arthritis.
    Valerio V; Kwok M; Loewen H; Winkler J; Mody GM; Scuccimarri R; Meltzer M; Mengistu Y; Feldman CH; Weinblatt ME; Lacaille D; Hitchon CA; Colmegna I
    Clin Rheumatol; 2021 Apr; 40(4):1259-1271. PubMed ID: 32876784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.
    Smolen JS; Landewé R; Breedveld FC; Dougados M; Emery P; Gaujoux-Viala C; Gorter S; Knevel R; Nam J; Schoels M; Aletaha D; Buch M; Gossec L; Huizinga T; Bijlsma JW; Burmester G; Combe B; Cutolo M; Gabay C; Gomez-Reino J; Kouloumas M; Kvien TK; Martin-Mola E; McInnes I; Pavelka K; van Riel P; Scholte M; Scott DL; Sokka T; Valesini G; van Vollenhoven R; Winthrop KL; Wong J; Zink A; van der Heijde D
    Ann Rheum Dis; 2010 Jun; 69(6):964-75. PubMed ID: 20444750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis.
    Lau CS; Chia F; Dans L; Harrison A; Hsieh TY; Jain R; Jung SM; Kishimoto M; Kumar A; Leong KP; Li Z; Lichauco JJ; Louthrenoo W; Luo SF; Mu R; Nash P; Ng CT; Suryana B; Wijaya LK; Yeap SS
    Int J Rheum Dis; 2019 Mar; 22(3):357-375. PubMed ID: 30809944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines.
    Conley B; Bunzli S; Bullen J; O'Brien P; Persaud J; Gunatillake T; Nikpour M; Grainger R; Barnabe C; Lin I
    Clin Rheumatol; 2023 Sep; 42(9):2267-2278. PubMed ID: 37291382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology.
    Ho CTK; Mok CC; Cheung TT; Kwok KY; Yip RML;
    Clin Rheumatol; 2019 Dec; 38(12):3331-3350. PubMed ID: 31485846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
    Ramiro S; Gaujoux-Viala C; Nam JL; Smolen JS; Buch M; Gossec L; van der Heijde D; Winthrop K; Landewé R
    Ann Rheum Dis; 2014 Mar; 73(3):529-35. PubMed ID: 24401994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.
    Bykerk VP; Akhavan P; Hazlewood GS; Schieir O; Dooley A; Haraoui B; Khraishi M; Leclercq SA; Légaré J; Mosher DP; Pencharz J; Pope JE; Thomson J; Thorne C; Zummer M; Bombardier C;
    J Rheumatol; 2012 Aug; 39(8):1559-82. PubMed ID: 21921096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer and Rheumatoid Arthritis.
    Pundole X; Suarez-Almazor ME
    Rheum Dis Clin North Am; 2020 Aug; 46(3):445-462. PubMed ID: 32631599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Louthrenoo W; Kasitanon N; Katchamart W; Aiewruengsurat D; Chevaisrakul P; Chiowchanwisawakit P; Dechanuwong P; Hanvivadhanakul P; Mahakkanukrauh A; Manavathongchai S; Muangchan C; Narongroeknawin P; Phumethum V; Siripaitoon B; Suesuwan A; Suwannaroj S; Uea-Areewongsa P; Ukritchon S; Asavatanabodee P; Koolvisoot A; Nanagara R; Totemchokchyakarn K; Nuntirooj K; Kitumnuaypong T
    Int J Rheum Dis; 2017 Sep; 20(9):1166-1184. PubMed ID: 28730640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.
    Gaujoux-Viala C; Smolen JS; Landewé R; Dougados M; Kvien TK; Mola EM; Scholte-Voshaar M; van Riel P; Gossec L
    Ann Rheum Dis; 2010 Jun; 69(6):1004-9. PubMed ID: 20447954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis].
    Chinese Rheumatology Association
    Zhonghua Nei Ke Za Zhi; 2018 Apr; 57(4):242-251. PubMed ID: 29614581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.
    Ramiro S; Sepriano A; Chatzidionysiou K; Nam JL; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; Bijlsma JW; Burmester GR; Scholte-Voshaar M; Falzon L; Landewé RBM
    Ann Rheum Dis; 2017 Jun; 76(6):1101-1136. PubMed ID: 28298374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kuwait association of rheumatology 2018 treatment recommendations for patients with rheumatoid arthritis.
    Alhajeri H; Abutiban F; Al-Adsani W; Al-Awadhi A; Aldei A; AlEnizi A; Alhadhood N; Al-Herz A; Alkandari W; Dehrab A; Muhanna Ghanem AA; Hasan E; Hayat S; Saleh K; Tarakmeh H; Ali Y
    Rheumatol Int; 2019 Sep; 39(9):1483-1497. PubMed ID: 31309293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immediate treatment with tumour necrosis factor inhibitors in synthetic disease-modifying anti-rheumatic drugs-naïve patients with rheumatoid arthritis: results of a modified Italian Expert Consensus.
    Bortoluzzi A; Valesini G; D'Angelo S; Frediani B; Bazzichi L; Afeltra A; Paolazzi G; Doria A; Meroni PL; Govoni M
    Rheumatology (Oxford); 2018 Oct; 57(57 Suppl 7):vii32-vii41. PubMed ID: 30289538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis.
    Fautrel B; Pham T; Mouterde G; Le Loët X; Goupille P; Guillemin F; Ravaud P; Cantagrel A; Dougados M; Puéchal X; Sibilia J; Soubrier M; Mariette X; Combe B; ;
    Joint Bone Spine; 2007 Dec; 74(6):627-37. PubMed ID: 18037319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.